Cancer Research AACR Membership Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5023-5029, October 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, L.
Right arrow Articles by Kern, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, L.
Right arrow Articles by Kern, F. G.
[Cancer Research 59, 5023-5029, October 1, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

Overexpression of Fibroblast Growth Factor 1 in MCF-7 Breast Cancer Cells Facilitates Tumor Cell Dissemination but Does Not Support the Development of Macrometastases in the Lungs or Lymph Nodes1

Lurong Zhang, Samir Kharbanda, Sandra W. McLeskey and Francis G. Kern2

Lombardi Cancer Center [L. Z., S. K., S. W. M.], Department of Cell Biology [L. Z.], Department of Pharmacology [S. W. M.], and the School of Nursing [S. W. M.], Georgetown University Medical Center, Washington, D.C. 20007; and Drug Discovery Division, Southern Research Institute, Birmingham, Alabama 35255-5305 [F. G. K.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Mice bearing primary tumors produced by LacZ-tagged MCF-7 human breast carcinoma cells transfected with fibroblast growth factor (FGF) 1 have frequent micrometastases, but macrometastases are not observed. i.v. injection of FGF-1-transfected tumor cells produced no pulmonary macrometastases, and removal of primary tumors resulted in the disappearance of spontaneous micrometastases. Thus, failure of micrometastases to proliferate was not due to inhibitory factors released from the primary tumor, and the presence of the primary tumor is required for maintenance of the micrometastases. This indicates that the micrometastases result from continued seeding from the primary tumor balanced by clearance from the metastatic site. Tumor emboli trapped in the vessels of lungs and lymph nodes and single tumor cells observed in the pulmonary vein implied that FGF-1-overexpressing MCF-7 cells are deficient in their ability to extravasate. The frequency of tumor cells incorporating bromodeoxyuridine was consistently lower in lung tissues when compared with primary tumors, indicating that disseminated tumor cells were unable to maintain a high rate of proliferation. Increased angiogenesis resulting from FGF-1 production by the transfected cells with a concomitant increased rate of intravasation into developing blood vessels may be the underlying determinant of spontaneous micrometastasis produced by these cells when compared with parental MCF-7 cells.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Metastasis is the product of complicated interactions between tumor cells and stroma. Tumor cells must detach from the primary tumor, enter the circulation, extravasate at distant sites, and proliferate in the parenchyma of distant organs (1, 2, 3) . Although a number of factors have been shown to be involved in this process, including proteases (4 , 5) , adhesion molecules (4 , 6 , 7) , motility factors (3) , and angiogenic factors (1 , 8) , the precise mechanism of the metastatic process remains unclear. However, a sufficient blood supply via tumor microvessels is critical for both primary tumor growth and secondary metastasis (1 , 8 , 9) . Therefore, increased angiogenesis may increase opportunities for intravasation of tumor cells into the circulation (10 , 11) .

A recent report (12) suggests that intravasation mediated by activation of a plasmin-metalloproteinase cascade may be a rate-limiting step in the metastatic process. However, circulating tumor cells can commonly be found in patients with many types of solid tumors [Refs. 10 and 13, 14, 15, 16, 17, 18, 19, 20, 21 (reviewed in Ref. 13 )]. Thus, the importance of intravasation as a rate-limiting step of metastasis is currently under debate. Likewise, recent studies seem to indicate that extravasation is a relatively common event and therefore perhaps not rate-limiting (5 , 22) . However, others have proposed that all sequential steps of metastasis are rate-limiting (1) and selective (23) . Although the reasons for these controversies may have to do with the validity of the particular models of metastasis used, it is also possible that for different tumors, different steps of the metastatic process are either more or less important as rate-limiting steps.

In previous studies, we have demonstrated that transfection of FGFs3 can confer an antiestrogen-resistant and hormone-independent in vivo growth phenotype to MCF-7 breast carcinoma cells. In addition, FGF-1 or FGF-4 overexpression confers a metastatic phenotype on these nonmetastatic and noninvasive cells (24, 25, 26) . The results of the current study indicate that overexpression of FGF-1 by MCF-7 cells can induce transient microdeposits of tumor cells in vessels of distant organs that do not seem to extravasate efficiently into the parenchyma and may fail to proliferate at the distant site. We submit that the increased dissemination of tumor cells is a result of enhanced intravasation via the large number of FGF-1-stimulated blood vessels within the primary tumors. Thus, this xenograft tumor model provides evidence that the processes of intravasation and extravasation can be distinct, requiring different attributes, and, together with control parental MCF-7 cells, provides the opportunity to study these processes separately.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
FGF-1 clone 18 is a clonal cell line of LacZ-transfected MCF-7 breast carcinoma cells retransfected with the cDNA for human FGF-1 (26) . To isolate the clone 18-lung cell line, 10 million clone 18 tumor cells were injected into the mammary fat pads of ovariectomized nude mice treated with 17ß-estradiol (0.72 mg/pellet; 60-day release). After 40 days, 100 mg of lung tissue of each mouse were sterilely harvested, minced, and digested in 1 ml of a mixture of 800 µg/ml collagenase (C-9891; Sigma, St. Louis, MO), 100 mg/ml bovine pancreatic protease (P-4630; Sigma), and 0.5 mg/ml bovine pancreatic DNase (DN-25; Sigma) in IMEM (Biofluids Inc., Rockville, MD) at 37°C for 1 h. After washing with IMEM, the disassociated cells were cultured in 10% fetal bovine serum-IMEM containing 500 µg/ml G418 [the expression vector for FGF-1 confers G418 resistance (26) ]. Two individual colonies surviving in G418-containing media were harvested and expanded as clonal cell lines. In this study, clone 2 was used.

X-Gal Staining for ß-Galactosidase Activity in Tissues.
Harvested lungs and lymph nodes were dissected free of surrounding fat and fixed and stained with X-gal, as described previously (25) . After further fixation in 10% phosphate-buffered formalin, the approximate number of foci of blue-stained metastatic tumor cells present within the lymph node or lung was estimated with an Olympus SZH dissecting microscope. The following scoring system was used to score the degree of metastasis, based on the estimated counts: (a) -, no blue spots; (b) +, about 1–50 blue spots; (c) ++, about 50–100 blue spots; (d) +++, about 100–200 blue spots; and (e) ++++, >200 blue spots.

Experimental Lung Metastasis Assay.
One million clone 18 or clone 18-lung tumor cells were injected into the tail veins of ovariectomized nude mice supplemented with 17ß-estradiol (0.72 mg s.c. pellet; 60-day release). Representative mice were sacrificed at 2, 24, 48, and 72 h and 1 week and 2 weeks after injection. Lung metastases were evaluated as described above.

Analysis of Extent of Metastases after Primary Tumor Removal.
Five million tumor clone 18 or clone 18 lung cells were injected each of two mammary fat pads located on opposite sides of 4–6-week-old ovariectomized nude mice (athymic NCR nu/nu; National Cancer Institute, Frederick, MD) supplemented with 17ß-estradiol (0.72 mg s.c. pellet; 60-day release) as described previously (26) . Tumors sizes were measured twice weekly with calipers. On days 19 and 25 after inoculation, one mouse from each cell line was checked for the extent of lung metastases as described above. On day 26 after inoculation, tumor-bearing mice were randomly divided into three groups (5–10 mice/group, depending on the number of tumor-bearing mice). The mice in one of the groups were sacrificed to determine the incidence (the number of mice with metastases/total mice examined) and the extent of the metastases, using the scoring system above, in both the lungs and lymph nodes. The mice in another group (the remain group) were sacrificed 32 days after tumor cell injection, when the tumors reached a size that necessitated sacrifice of the mouse. Mice in the third group (the removal group) had the tumors resected. At 14 and 44 days after tumor resection, one mouse from each removal group was sacrificed to assess metastases. Fifty days after tumor removal, all of the remaining mice were sacrificed, and lung and lymph node metastases were assessed. Two mice in the removal groups, one for each cell line, had tumors reappear at the site of the tumor excision. They were sacrificed at the same time as the rest of the mice (50 days after excision) and comprise the regrowth group.

PECAM-1 and BrdUrd Immunohistochemistry.
PECAM-1 staining of tumor-associated mouse endothelial cells was accomplished with a rat monoclonal antibody against murine PECAM-1 (Mec 13.3; 01951D; PharMingen, San Diego, CA), as described previously (27) . Primary tumors and lung tissues from mice receiving i.p. injections of 1 mg of BrdUrd (B-5002; Sigma) in PBS 8 h before sacrifice were processed for immunohistochemical assessment of tumor cell proliferation as described previously (27) . Briefly, tumors and tissues were fixed in 10% buffered formalin, and 5-µm-thick paraffin sections of lungs and primary tumors were deparaffinized and rehydrated in graded alcohols. Endogenous peroxidase activity was blocked with 0.3% H2O2 in methanol for 30 min. The slides were then incubated in a blocking solution of 5% BSA + 2% normal rabbit serum in PBS for 1 h. Rat anti-BrdUrd primary antibody (MAS 250; Accurate Antibodies, Westbury, NY) was added at a 1:32 dilution in blocking solution, and the slides were incubated for 1 h at room temperature. Biotinylated rabbit antirat IgG (5 µg/ml) was applied for 1 h, and, after washing with PBS, a streptavidin-conjugated peroxidase solution (BA 4000; Vector Laboratories, Burlingame, CA) was applied for 1 h at room temperature. The BrdUrd incorporation in tissues was then visualized by incubation with 0.05% diaminobenzidine and 0.01% H2O2 for 15 min. The slides were counterstained with hematoxylin, dehydrated, coverslipped, and examined using an Olympus AH-2 microscope. For primary tumors, the percentage of BrdUrd-positive cells was determined by counting 100 cells in three to five random fields (x200) from each of five different tumors. For sections from lung tissues, the number of BrdUrd-positive cells/number of total X-gal-stained cells was determined for six different tumor-bearing animals by counting multiple fields and sections. Over 1600 X-gal-stained cells were counted.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
FGF-1-overexpressing MCF-7 Cells Fail to Develop Experimental Lung Metastasis.
Although the MCF-7 cell line was established from a pleural effusion of a 69-year patient with metastatic carcinoma (28) , the cells are poorly metastatic and poorly invasive (12 , 25 , 26) . We have previously reported that transfection of LacZ-tagged MCF-7 breast carcinoma cells with FGF-1, FGF-4, or VEGF165 produced cell lines with increased spontaneous metastatic potential in comparison with the parental MCF-7 cells (24, 25, 26 , 29) . A clonal MCF-7 derivative that stably expresses a transfected bacterial LacZ gene was used as the recipient in these studies, allowing a sensitive X-gal staining assay to be used to semiquantitatively detect the presence of micrometastases in lungs, lymph nodes, and other organs (25) . Overexpression of either VEGF, FGF-4, or FGF-1 allows disseminated tumor cells to be detected in large numbers and with essentially 100% frequency in either the lungs or lymph nodes of tumor-bearing mice. In contrast, the frequency with which disseminated tumor cells can be detected in estrogen-supplemented mice bearing parental cell tumors is essentially zero, even when these tumors are the same size as the tumors composed of either FGF- or VEGF-overexpressing cells.

Despite the large number of tumor cells present within the lungs of either FGF or VEGF tumor-bearing mice, macrometastastic tumor nodules were never observed. This raised the possibility that the detection of X-gal-stained cells in distant organs of tumor-bearing mice was due to the presence of the cells that had been introduced into the circulation at the time of tumor cell injection and, as a result of angiogenic growth factor overexpression, were able to persist in these organs until the time of animal sacrifice.

To address this possibility, one million clone 18 cells, which overexpress FGF-1, were injected into the tail veins of nude mice, and metastases were examined in the lungs after harvesting at 2, 24, 48, and 72 h and 1 week and 2 weeks after the tail vein injection. Two h after tumor cell injection, there were abundant blue-stained tumor cells in the lung. However, the number of these cells decreased rapidly with increasing time, and at 72 h or later, no blue-stained tumor cells were visible (Fig. 1Citation and Table 1Citation ).



View larger version (82K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. i.v. injected FGF-1-overexpressing MCF-7 breast tumor cells disappear from lungs by 72 h after injection. One million FGF-1-transfected MCF-7 breast cancer cells (clone 18 or clone 18 lung) were injected into the tail veins of nude mice. At the indicated times, five mice in each group were sacrificed. The lungs were stained with X-gal and photographed (x7.5) using an Olympus SZH dissecting microscope. A–D, representative lungs of mice injected with clone 18 cells; E–H, lung from mice injected with clone 18 lung cells. A and E, 2 h; B and F, 24 h; C and G, 48 h; D and H, 72 h.

 

View this table:
[in this window]
[in a new window]

  		Table 1 i.v. injection of FGF-1-transfected MCF-7 breast cancer cells does not produce permanent lung metastasis

 
Only a small proportion of circulating tumor cells may have the ability to grow in metastatic sites (2) . Therefore, the above-mentioned results might be explained by a lack of lung-colonizing ability of the large majority of the cells we injected into the tail vein. To rule out this explanation, we established the clone 18 lung cell line that was derived by retrieving clone 18 tumor cells from the spontaneous metastases present in the lungs of mice bearing primary clone 18 tumors that grew after mammary fat pad injection. This cell line could form well-vascularized tumors in nude mice with or without estrogen supplementation, indicating that those cells that were present in the lungs continued to produce and respond to FGF. These cells were also injected into the tail veins of recipient mice as described above. The results were similar to those obtained with unselected clone 18 cells (Fig. 1Citation and Table 1Citation ). Thus, the tail vein injections seeded the circulation with many more tumor cells than would be expected from the random accidental traumatic intravasation of cells at the time of mammary fat pad inoculation. Nonetheless, neither unselected cells nor cells selected from a metastatic site produced micrometastases. Therefore, we conclude that spontaneous lung micrometastases are not the result of a one-time seeding of cells into the circulation that might result from tissue trauma or vessel injury at the time of mammary fat pad injection.

Removal of Primary Tumors Results in the Disappearance of Lung Metastases.
Long-lived secreted angiogenesis inhibitors that are produced by the primary tumor have been described which inhibit the growth of disseminated tumor cells; the best characterized of these are angiostatin and endostatin (30 , 31) . To determine whether the FGF-1-transfected MCF-7 primary tumors were producing a similar substance that could overcome the growth-stimulatory effect that would be expected from the production of FGF-1, an experiment similar to the one used by others to demonstrate the dependence of the metastasis-inhibiting activity of angiostatin on the continued presence of the primary tumor was performed. Mice were injected with either FGF-1 clone 18 or clone 18 lung cells. Tumors were allowed to develop to an approximate size of 1 cm3. All of the animals from a group that were sacrificed at this point had numerous micrometastatic deposits of blue-stained cells in either the lungs or lymph nodes (Fig. 2Citation and Table 2Citation ). The tumors were resected in a second group of mice, and animals from this group were sacrificed 2, 6, and 7 weeks later. No evidence of macrometastases was seen in any of the animals in this group. Instead, with the exception of two animals in which the primary tumors redeveloped due to incomplete resection, both the lungs and lymph nodes were completely cleared of any blue-stained cells.



View larger version (93K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Disappearance of spontaneous metastases after the removal of primary tumors. Mice were injected in the mammary fat pads at two sites with 5 million clone 18 or clone 18 lung cells. On day 28, mice were randomized into control and removal groups. Control group mice were sacrificed and evaluated for metastases. Removal group mice were subjected to surgical excision of the tumors. A, spontaneous lung metastases in a control mouse 26 days after tumor cell injection. B, lungs of a mouse sacrificed 14 days after removal of the primary tumors. C, lungs of one of the two mice originally in the removal group whose tumors were incompletely excised and regrew (the regrowth group) 50 days after excision of the original tumors. D, lymph node metastases in a control mouse 26 days after tumor cell injection. E, lymph nodes of a mouse sacrificed 14 days after the removal of primary tumors.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Spontaneous metastasis produced by FGF-1-transfected MCF-7 breast cancer cells are cleared after tumor removal

 
These data suggest that the inability of micrometastases to grow into macrometastases is not due to the release of an inhibitor from the primary tumor and that the existence of the primary tumor is required for maintenance of the micrometastases. The failure of the clone 18 lung cell line to develop tumor nodules further suggests that the tumor cells present in the lungs of tumor-bearing mice are not there because they have a selective advantage. Thus the data imply that the micrometastases are the result of the continual shedding of tumor cells into the circulation from the site of the primary tumor.

Because micrometastases do not result from primary tumors produced by LacZ-transfected MCF-7 cells (24, 25, 26 , 29) , micrometastases produced by the FGF-1 transfectants could be due to increased intravasation of the tumor cells into the more abundant blood vessels stimulated by FGF in the primary tumors (26) . Immunohistochemistry using an antibody specific for murine PECAM-1, a marker for mouse endothelial cells, shows increased blood vessel density in the tumors produced by FGF-1-transfected cells compared with those produced by the parental LacZ-expressing MCF-7 cell line ML-20 (Fig. 3)Citation . We hypothesize that the production of an angiogenic growth factor and the resulting increased density of intratumoral blood vessels provide avenues for the intravasation of tumor cells and thereby facilitate micrometastasis formation.



View larger version (128K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Immunohistochemistry for murine PECAM-1 in tumors formed by control vector- or FGF-1-transfected MCF-7 cells. PECAM-1 immunoreactive blood vessels are greatly increased in tumors formed by FGF-1-transfected clone 18 cells (A) when compared with tumors formed by a pooled polyclonal population of control vector-transfected MCF-7 cells (B). Bars, 50 µm.

 
Tumor Cells in Micrometastases Fail to Extravasate.
Because we never observed pulmonary macrometastases in mice bearing tumors produced by FGF-transfected cells, and because it seems that abundant tumor cells gained entry to the circulation, we examined lung and lymph node specimens closely to see whether tumor cells were contained within vessels or had invaded the parenchyma of the lung or lymph node. Careful examination revealed that whereas a small number of tumor cells appeared in the parenchyma of the lungs and lymph nodes, many multiple-cell tubular aggregates of tumor cells could be seen within the microvasculature of the lungs (Fig. 4A)Citation or in the lymphatic vessels (Fig. 4B)Citation . These results imply that the large majority of tumor cells contained in "micrometastases" are actually confined to the vessels of distant organs. Furthermore, individual X-gal-positive cells were visible in large pulmonary veins (Fig. 4C)Citation , implying that they were in the process of being cleared from the lung.



View larger version (164K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Failure of cells in micrometastatic emboli to extravasate or maintain a high rate of proliferation. X-gal staining was performed as described in "Materials and Methods," followed by methyl green counterstaining. Many blue X-gal-stained tumor cells are visible within the vessels of the lung (A) and lymph node (B) of mice bearing tumors produced by clone 18 cells. Fast-red-stained nuclei in these sections are the result of a TUNEL assay for apoptotic cells that was performed on these sections (see "Discussion"). Black arrows point to single blue-stained cells that are visible in a large vein of the lung (C), suggesting that they are being cleared from the metastatic site. BrdUrd incorporation in breast tumor cells present within primary tumors (D) or lung tissues (E) is shown. Diaminobenzidine stains the nuclei containing incorporated BrdUrd brown. Only the tumor cells present in lung tissues were stained blue with X-gal. The primary tumor was not stained with X-gal. The white arrow points to the single BrdUrd-positive tumor cell present in this field. Bars, 20 µm.

 
We also sought to determine whether cells comprising the micrometastases had a lower proportion of proliferating cells when compared with cells within the primary tumor by determining the percentage of tumor cells that had incorporated BrdUrd over an 8-h period before animal sacrifice. We consistently observed that primary tumors were composed of 25–35% BrdUrd-positive cells, whereas the frequency of BrdUrd-positive tumor cells present in lung tissues was consistently between 5% and 15% (Fig. 4, D and E)Citation . These results suggest that most of the cells comprising the micrometastases formed by the FGF-1 transfectants lack the ability to extravasate or proliferate. In addition, they imply that the deposits of cells within the vasculature of the lung are dynamic collections of cells that result from a balance between continual seeding from the primary tumor and continual clearance.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Although our previous studies have shown that overexpression of angiogenic factors could increase the incidence of micrometastases of MCF-7 breast carcinoma cells (24, 25, 26 , 29) , macrometastases were never found, and none of the tumor-bearing mice would eventually die of lung metastasis. In the present study, we demonstrate that micrometastases do not originate from the seeding of tumor cells into the circulation as a result of the trauma of inoculation but probably result from an increased incidence of intravasation, possibly as a result of increased tumor-associated vessels. Moreover, it would seem that most of the disseminated cells are unable to extravasate and remain trapped in the pulmonary and lymphatic vessels. There seems to be a dynamic equilibrium between cells arriving from the primary tumor and those leaving or being cleared from the metastatic site. Because the ability of tumor cells to form macrometastases depends on their completion of the steps of intravasation into the local circulation, dissemination throughout the circulatory system, arrest in the microvasculature of metastatic sites, extravasation, and growth in the parenchyma of the metastatic site (1 , 2) , FGF-1-transfected MCF-7 cells may be unable complete the final two steps in the process of metastasis.

Using tumor cells placed atop a wounded CAM, where they have ready access to a highly vascularized capillary bed, others have shown that the breaching of the vascular wall is a rate-limiting step in intravasation and may be a rate-limiting step for metastasis (12) . In our model system, the tumor cells present within highly angiogenic tumors may be able to intravasate and be disseminated to distant sites without their having acquired a mechanism allowing them to breach an intact vessel wall. The high rate of ongoing neoangiogenesis within the FGF-1-overexpressing breast tumors may increase the probability of tumor cells having direct access to immature and incompletely formed vessels. However, if this same vessel-breaching mechanism is also required for extravasation, the metastatic process would be aborted at this stage.

Although we postulate that the discovery of increased spontaneous micrometastases in mice bearing tumors produced by the transfected cell lines is the result of an increased rate of intravasation due to increased angiogenesis in the primary tumor, other factors could be responsible for this phenomenon. Intravascular arrest of circulating tumor cells could be increased with the FGF-1 transfectants in comparison to that of wild-type MCF-7 cells. However, our preliminary analysis of expression of integrins and attachment factors has failed to detect evidence of changed expression in the FGF-1 transfectants compared with the parental MCF-7 cells (data not shown), arguing against increased vascular arrest as an explanation for the increased rate of micrometastases in our transfectants.

Proteases are thought to be essential for tumor cells to degrade the basement membrane (4) . Therefore, the failure of the tumor cells to extravasate from the circulation could be due to insufficient protease expression or expression of an ineffective or inactive protease. Others have found that transfection of FGF-2 into renal carcinoma cells increased the metastatic potential of these cells and also increased the expression of MMP-2 (32) . We have assessed protease activity using gelatin zymography, and we see no distinct differences in MMP-2 or MMP-9 activity in FGF transfectants compared with the nonmetastatic parental MCF-7 cells (data not shown). However, many other proteases, including receptor-localized plasminogen activators, could be important and may be needed in concert with MMP expression for an invasive phenotype (12 , 33 , 34) . FGF-2 induces the expression of uPA in endothelial cells and in L6 myoblast cells or Chinese hamster ovary cells transfected with FGF receptors (35, 36, 37) . Our preliminary studies suggest that FGF-1 or FGF-4 overexpression also induces the expression of uPA mRNA in MCF-7 cells (38) . However, overexpression of either FGF has no effect on uPA receptor mRNA.4 Thus a FGF-induced increase in protease expression may not result in increased invasiveness if the protease is not subsequently localized properly via an interaction with membrane-bound receptors on the tumor cell, because this process appears to be necessary for activation of a protease cascade (34) . Moreover, increased expression of protease inhibitors might also play a role in the failure to extravasate. Studies examining these issues are ongoing in our laboratories.

The view of extravasation as being a rate-limiting step for metastasis has recently been challenged. Nonmetastatic and metastatic cells do equally well in extravasation assays in chick CAM or mouse liver, regardless of their expression levels of adhesion molecules, proteases, or oncogenes (5 , 22 , 39, 40, 41, 42, 43) . Our result showing that FGF-1-transfected cells disappeared from the lung by 24 h after i.v. injection is in apparent conflict with reports that the majority of i.v. injected cells have extravasated by 24–72 h (22 , 39, 40, 41 , 43) . Explanations may include differences between the metastatic sites examined. CAM is an avian embryonic tissue that might not present such a formidable barrier to extravasation or might express different adhesion molecules when compared with the vessels of the lung or lymph node in an adult mouse. Liver vessels might also express different adhesion molecules. Moreover, liver contains fenestrated endothelium in the sinusoids, which could possibly facilitate extravasation. Extravasated cells have been observed as single cells in the parenchyma of the liver up to 3 weeks after extravasation (39) . Even if it is assumed that the large number of transfected cells that we injected i.v. do extravasate, their disappearance from lung within 24 h is again at odds with these reports. The presence of many tumor cells in large pulmonary veins supports our belief that the majority of our transfected cells do fail to extravasate in the lung and are flushed away by hemodynamic forces. These results are also in conflict with those of others, because they find no cell loss associated with i.v. injected cells (22 , 40) . Of course, we cannot exclude the possibility that some of our cells can extravasate, and certainly postextravasation events are important determinants in the formation of macrometastasis (22) .

The failure of our micrometastatic tumor cells to develop into macrometastases could also be due to a failure to grow or an accelerated degree of apoptosis. It has been reported that intravascular proliferation is rare (22) . Our efforts to compare labeling indices for BrdUrd incorporation between micrometastases and primary tumors were hampered by the small number of micrometastatic cells and the small number of animals that have been examined thus far. Whereas repeated injections of BrdUrd over time might be required to determine the actual proliferative capability of the disseminated tumor cells, our results at this point suggest that BrdUrd incorporation indices may be lower in micrometastases than in primary tumors. Because our overall results suggest that the micrometastases are transient in nature, much of this incorporation may have occurred while the tumor cells were physically present within the primary tumor. When they are expanded and reinoculated into ovariectomized nude mice, breast tumor cell lines reestablished from the cells present in either the lungs or lymph nodes continue to exhibit in vivo growth phenotypes that we have previously shown to be dependent on the autocrine and paracrine effects of FGF-1 overexpression (44) . Thus it would appear that the cells present within these tissues continue to be able to produce and respond to FGF-1. This suggests that whereas the autocrine and paracrine effects of FGF-1 overexpression, in combination with the microenvironment present within the mammary fat pad, provide a strong mitogenic stimulus to tumor cells, the microenvironment within the lungs or lymph nodes does not permit similar effects to be manifested in disseminated tumor cells. Because FGF-1-overexpressing cells demonstrate an enhanced anchorage-independent growth phenotype in vitro (26 , 44) , the failure of the cells to proliferate once they are disseminated to lungs and lymph nodes is somewhat unexpected. Moreover, the failure to proliferate raises the question of whether these cells actually have enhanced metastatic capabilities beyond their increased ability to gain entry into the circulation. Others have reported that MCF-7 cells can form bone metastases 6–8 weeks after intracardiac injection into the left ventricle (45) , a delivery route that bypasses the pulmonary circulation and the subsequent entrapment of tumor cells within lung capillaries. It remains to be determined whether FGF-overexpressing MCF-7 cells have a growth advantage at other sites after intracardiac or i.p. injection.

We also attempted to use a TUNEL assay to determine whether the frequency of apoptotic cells was greater in micrometastases than in tumors. Our preliminary studies did indicate that TUNEL labeling indices were higher in micrometastases than in primary tumors (data not shown). However, this analysis was also hampered by the comparatively small number of micrometastatic cells and the difficulty in identifying labeled cells as tumor cells, especially in lymph nodes, which would be expected to contain apoptotic immune cells. In addition, it was recently discovered that MCF-7 cells do not produce a functional caspase 3, the enzyme largely responsible for the DNA laddering and associated DNA strand breaks detected with the TUNEL assay (46) . This recent finding makes it likely that the TUNEL assay may not be an appropriate measure of the extent of ongoing apoptosis in either MCF-7 xenograft tumors or disseminated tumor cells. The current lack of another suitable in situ assay for apoptosis may make it difficult to address this question.

Overall, the results of this study indicate that tumor angiogenesis facilitates intravasation of tumor cells into the circulation from primary tumors. However, we show that this is not sufficient for the formation of macrometastases. Thus, our data imply that the factors that confer upon tumor cells the ability to extravasate and to grow in distant sites may be key determinants in the formation of clinically significant macrometastases. Future studies aimed at discovering determinants that can further enhance the metastatic ability of FGF-1-transfected MCF-7 cells could include investigations into the role of various attachment factors, motility factors, modulators of apoptosis, or activators of proteolytic cascades involved in tumor cell migration through the endothelial cell layer and in basement membrane invasion. The increased capacity for autonomous hormone-independent growth and tumor cell dissemination that occurs as a result of overexpression of this angiogenic growth factor should make this a useful model for such studies.


   ACKNOWLEDGMENTS
 
Animal protocols for this work were approved by the Georgetown University Animal Care and Use Committee. Animal work was done in the Lombardi Center Animal Research Resource supported by National Cancer Institute Center Grant P30 CA51008.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grant CA50376 and the Adolph Weil Endowed Chair at Southern Research Institute (to F. G. K.); NIH Grant CA71545 and Department of Defense Grant DAMD BC97-1820 (to L. Z.); NIH Grant CA66154 and Department of Defense Grant DAMD 17-94-4173 (to S. W. M.). L. Z. was a Susan Komen research fellow. Back

2 To whom requests for reprints should be addressed, at Southern Research Institute, P. O.Box 55305, 2000 Ninth Avenue South, Birmingham, AL 35255-5305. Phone: (205) 581-2480; Fax: (205) 581-2877; E-mail: kern{at}sri.org Back

3 The abbreviations used are: FGF, fibroblast growth factor; IMEM, improved minimal essential medium; X-gal, 5-bromo-4-chloro-3-indolyl ß-D-galactopyranoside; BrdUrd, bromodeoxyuridine; uPA, urokinase plasminogen activator; CAM, chorioallantoic membrane; MMP, matrix metalloproteinase; TUNEL, terminal deoxynucleotidyl transferase-mediated nick end labeling; PECAM-1, platelet/endothelial cell adhesion molecule 1; VEGF, vascular endothelial growth factor. Back

4 S. McLeskey, unpublished data. Back

Received 4/ 2/99. Accepted 8/ 6/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ellis L. M., Fidler I. J. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
  2. Weiss L. Metastatic inefficiency. Adv. Cancer Res., 54: 159-211, 1990.[Medline]
  3. Woodhouse E. C., Chuaqui R. F., Liotta L. A. General mechanisms of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.[Medline]
  4. Stetler-Stevenson W. G., Liotta L. A., Kleiner D. E. J. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J., 7: 1434-1441, 1993.[Abstract]
  5. Chambers A. F., Matrisian L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.[Abstract/Free Full Text]
  6. Zetter B. R. Adhesion molecules in tumor metastasis. Semin. Cancer Biol., 4: 219-229, 1993.[Medline]
  7. McCormick B. A., Zetter B. R. Adhesive interactions in angiogenesis and metastasis. Pharmacol. Ther., 53: 239-260, 1992.[Medline]
  8. Zetter B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 49: 407-424, 1998.[Medline]
  9. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.[Free Full Text]
  10. McCulloch P., Choy A., Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet, 346: 1334-1335, 1995.[Medline]
  11. Liotta L. A., Kleinerman J., Saidel G. M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res., 34: 997-1004, 1974.[Abstract/Free Full Text]
  12. Kim J., Yu W., Kovalski K., Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell, 94: 353-362, 1998.[Medline]
  13. Johnson P. W., Burchill S. A., Selby P. J. The molecular detection of circulating tumour cells. Br. J. Cancer, 72: 268-276, 1995.[Medline]
  14. Peck K., Sher Y. P., Shih J. Y., Roffler S. R., Wu C. W., Yang P. C. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res., 58: 2761-2765, 1998.[Abstract/Free Full Text]
  15. Racila E., Euhus D., Weiss A. J., Rao C., McConnell J., Terstappen L. W., Uhr J. W. Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. USA, 95: 4589-4594, 1998.[Abstract/Free Full Text]
  16. Sun Y., Lin J., Katz A. E., Fisher P. B. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res., 57: 18-23, 1997.[Abstract/Free Full Text]
  17. Mattano L. A. J., Moss T. J., Emerson S. G. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res., 52: 4701-4705, 1992.[Abstract/Free Full Text]
  18. Gross H. J., Verwer B., Houck D., Hoffman R. A., Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10-7. Proc. Natl. Acad. Sci. USA, 92: 537-541, 1995.[Abstract/Free Full Text]
  19. Moss T. J., Sanders D. G. Detection of neuroblastoma cells in blood. J. Clin. Oncol., 8: 736-740, 1990.[Abstract]
  20. Ts’o P. O., Pannek J., Wang Z. P., Lesko S. A., Bova G. S., Partin A. W. Detection of intact prostate cancer cells in the blood of men with prostate cancer. Urology, 49: 881-885, 1997.[Medline]
  21. Terstappen L. W., Rao C., Gross S., Kotelnikov V., Racilla E., Uhr J., Weiss A. Flow cytometry: principles and feasibility in transfusion medicine. Enumeration of epithelial derived tumor cells in peripheral blood. Vox Sang., 74 (Suppl. 2): 269-274, 1998.
  22. Chambers A. F., MacDonald I. C., Schmidt E. E., Koop S., Morris V. L., Khokha R., Groom A. C. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev., 14: 279-301, 1995.[Medline]
  23. Price J. E. Analyzing the metastatic phenotype. J. Cell. Biochem., 56: 16-22, 1994.[Medline]
  24. McLeskey S. W., Kurebayashi J., Honig S. F., Zwiebel J., Lippman M. E., Dickson R. B., Kern F. G. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res., 53: 2168-2177, 1993.[Abstract/Free Full Text]
  25. Kurebayashi J., McLeskey S. W., Johnson M. D., Lippman M. E., Dickson R. B., Kern F. G. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and lacZ. Cancer Res., 53: 2178-2187, 1993.[Abstract/Free Full Text]
  26. Zhang L., Kharbanda S., Chen D., Bullocks J., Miller D. L., Ding I. Y. F., Hanfelt J., McLeskey S. W., Kern F. G. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene, 15: 2093-2108, 1997.[Medline]
  27. McLeskey S. W., Tobias C. A., Vezza P. R., Filie A. C., Kern F. G., Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am. J. Pathol., 153: 1993-2006, 1998.[Abstract/Free Full Text]
  28. Engel L. W., Young N. A. Human breast carcinoma cells in continuous culture: a review. Cancer Res., 38: 4327-4339, 1978.[Abstract/Free Full Text]
  29. Bullocks J., Zhang L., Ding I. Y. F., McLeskey S. W., Tobias C. A., Miller D. L., Kern F. G. Overexpression of vascular endothelial growth factor (VEGF) in MCF-7 breast carcinoma cells facilitates growth in tamoxifen-treated nude mice and tumor cell dissemination. Proc. Am. Assoc. Cancer Res., 38: A3521 1997.
  30. O’Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.[Medline]
  31. O’Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.[Medline]
  32. Miyake H., Hara I., Yoshimura K., Eto H., Arakawa S., Wada S., Chihara K., Kamidono S. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res., 56: 2440-2445, 1996.[Abstract/Free Full Text]
  33. Quigley J. P., Armstrong P. B. Tumor cell intravasation alu-cidated: the chick embryo opens the window. Cell, 94: 281-284, 1998.[Medline]
  34. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J., 16: 2319-2332, 1997.[Medline]
  35. Sato Y., Rifkin D. B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol., 107: 1199-1205, 1988.[Abstract/Free Full Text]
  36. Rusnati M., Dell’Era P., Urbinati C., Tanghetti E., Massardi M. L., Nagamine Y., Monti E., Presta M. A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells. Mol. Biol. Cell, 7: 369-381, 1996.[Abstract]
  37. Dell’Era P., Mohammadi M., Presta M. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Mol. Biol. Cell, 10: 23-33, 1999.[Abstract/Free Full Text]
  38. Emanuels A. G., Kern F. G., McLeskey S. W. Urokinase plasminogen activator expression is up-regulated in MCF-7 cells transfected with angiogenic growth factors and is inhibited by estrogen treatment. Proc. Am. Assoc. Cancer Res., 40: 4561 1999.
  39. Morris V. L., Koop S., MacDonald I. C., Schmidt E. E., Grattan M., Percy D., Chambers A. F., Groom A. C. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin. Exp. Metastasis, 12: 357-367, 1994.[Medline]
  40. Koop S., MacDonald I. C., Luzzi K., Schmidt E. E., Morris V. L., Grattan M., Khokha R., Chambers A. F., Groom A. C. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res., 55: 2520-2523, 1995.[Abstract/Free Full Text]
  41. Koop S., Schmidt E. E., MacDonald I. C., Morris V. L., Khokha R., Grattan M., Leone J., Chambers A. F., Groom A. C. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc. Natl. Acad. Sci. USA, 93: 11080-11084, 1996.[Abstract/Free Full Text]
  42. MacDonald I. C., Schmidt E. E., Morris V. L., Chambers A. F., Groom A. C. Intravital videomicroscopy of the chorioallantoic microcirculation: a model system for studying metastasis. Microvasc. Res., 44: 185-199, 1992.[Medline]
  43. Koop S., Khokha R., Schmidt E. E., MacDonald I. C., Morris V. L., Chambers A. F., Groom A. C. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res., 54: 4791-4797, 1994.[Abstract/Free Full Text]
  44. Zhang L., Kharbanda S., Hanfelt J., Kern F. G. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res., 58: 352-361, 1998.[Abstract/Free Full Text]
  45. Yoneda T., Sasaki A., Mundy G. R. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat., 32: 73-84, 1994.[Medline]
  46. Janicke R. U., Sprengart M. L., Wati M. R., Porter A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 273: 9357-9360, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Guo, S. Ibaragi, T. Zhu, L.-Y. Luo, G.-F. Hu, P. S. Huppi, and C. Y. Chen
Nicotine Promotes Mammary Tumor Migration via a Signaling Cascade Involving Protein Kinase C and cdc42
Cancer Res., October 15, 2008; 68(20): 8473 - 8481.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Qu, S. Van Ginkel, A. M. Roy, L. Westbrook, M. Nasrin, Y. Maxuitenko, A. R. Frost, D. Carey, W. Wang, R. Li, et al.
Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors
Cancer Res., August 1, 2008; 68(15): 6232 - 6240.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al.
Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1
Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Paris and R. Sesboue
Metastasis models: the green fluorescent revolution?
Carcinogenesis, December 1, 2004; 25(12): 2285 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. D. Coletta, K. Christensen, K. J. Reichenberger, J. Lamb, D. Micomonaco, L. Huang, D. M. Wolf, C. Muller-Tidow, T. R. Golub, K. Kawakami, et al.
The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1
PNAS, April 27, 2004; 101(17): 6478 - 6483.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Kumar, H. Kishimoto, H. L. Chua, S. Badve, K. D. Miller, R. M. Bigsby, and H. Nakshatri
Interleukin-1{alpha} Promotes Tumor Growth and Cachexia in MCF-7 Xenograft Model of Breast Cancer
Am. J. Pathol., December 1, 2003; 163(6): 2531 - 2541.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Karpanen, M. Egeblad, M. J. Karkkainen, H. Kubo, S. Ylä-Herttuala, M. Jäättelä, and K. Alitalo
Vascular Endothelial Growth Factor C Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth
Cancer Res., March 1, 2001; 61(5): 1786 - 1790.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, L.
Right arrow Articles by Kern, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, L.
Right arrow Articles by Kern, F. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online